Market capitalization | $4.63b |
Enterprise Value | $4.04b |
P/E (TTM) P/E ratio | 90.98 |
EV/FCF (TTM) EV/FCF | 69.66 |
EV/Sales (TTM) EV/Sales | 16.75 |
P/S ratio (TTM) P/S ratio | 19.15 |
P/B ratio (TTM) P/B ratio | 5.22 |
Revenue growth (TTM) Revenue growth | 2,722.79% |
Revenue (TTM) Revenue | $241.52m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
10 Analysts have issued a Krystal Biotech, Inc. forecast:
10 Analysts have issued a Krystal Biotech, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 242 242 |
2,721%
2,721%
|
|
Gross Profit | 217 217 |
5,701%
5,701%
|
|
EBITDA | 72 72 |
155%
155%
|
EBIT (Operating Income) EBIT | 65 65 |
148%
148%
|
Net Profit | 52 52 |
276%
276%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Head office | United States |
CEO | Krish Krishnan |
Employees | 229 |
Founded | 2016 |
Website | www.krystalbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.